These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10565996)

  • 1. ISIS 2302. INXC ICAM1, Oligo-TCS.
    Drugs R D; 1999 Jan; 1(1):85-6. PubMed ID: 10565996
    [No Abstract]   [Full Text] [Related]  

  • 2. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
    Kahan BD; Stepkowski S; Kilic M; Katz SM; Van Buren CT; Welsh MS; Tami JA; Shanahan WR
    Transplantation; 2004 Sep; 78(6):858-63. PubMed ID: 15385805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT; Sitaraman SV
    Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GEM 132. Gene expression modulation 132.
    Drugs R D; 1999 Nov; 2(5):313-4. PubMed ID: 10728469
    [No Abstract]   [Full Text] [Related]  

  • 7. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
    Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY 720.
    Drugs R D; 1999 Jan; 1(1):78-80. PubMed ID: 10565994
    [No Abstract]   [Full Text] [Related]  

  • 10. Priliximab. Anti-CD4 MAb, CEN 000029, MT 412, cMT 412, Centara.
    Drugs R D; 1999 Jan; 1(1):95-6. PubMed ID: 10565999
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTI 322. Anti-CD2 monoclonal antibody, Lo-CD2-a, monoclonal antibody Lo-CD2-a.
    Drugs R D; 1999 Jan; 1(1):68-70. PubMed ID: 10565990
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEDI 500. Anti-TCR-alpha beta monoclonal antibody T10B9, G 022, T-10B9, T10B9, T10B9 monoclonal antibody, T10B9.1A31, T12A10.
    Drugs R D; 1999 Jan; 1(1):92-4. PubMed ID: 10565998
    [No Abstract]   [Full Text] [Related]  

  • 15. Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
    Drugs R D; 1999 Jan; 1(1):100-7. PubMed ID: 10566001
    [No Abstract]   [Full Text] [Related]  

  • 16. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
    Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ISIS-3521. Isis Pharmaceuticals.
    Li K; Zhang J
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic therapy for transplant vascular sclerosis.
    Bennett CF; Stepkowski SM
    Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
    [No Abstract]   [Full Text] [Related]  

  • 20. Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel.
    Drugs R D; 1999 Jan; 1(1):75-7. PubMed ID: 10565993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.